A Study of ABI-H2158 in Healthy Volunteers and Patients With Chronic Hepatitis B

  • STATUS
    Not Recruiting
  • participants needed
    80
  • sponsor
    Assembly Biosciences
Updated on 2 August 2021
Investigator
Assembly Biosiences
Primary Contact
University of Hong Kong, Queen Mary Hospital (4.4 mi away) Contact
+13 other location
cirrhosis
fibrosis
chronic hepatitis
hepatitis b e antigen

Summary

This three-part, Phase 1 protocol will be the first clinical study of ABI-H2158. Parts 1 and 2 will be a Phase 1a, dose-ranging assessment of ABI-H2158 in healthy adult volunteers. If the dose-related safety, tolerability, and pharmacokinetics (PK) of ABI-H2158 in healthy volunteers are deemed satisfactory, then the study will advance to Part 3, a Phase 1b, dose-ranging assessment of ABI-H2158 in non-cirrhotic, CHB patients.

Details
Condition Hepatitis B, chronic hepatitis b
Treatment ABI-H2158, Placebo for ABI-H2158
Clinical Study IdentifierNCT03714152
SponsorAssembly Biosciences
Last Modified on2 August 2021

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note